1169 related articles for article (PubMed ID: 29178633)
1. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
2. Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century.
Čivljak R; Giannella M; Di Bella S; Petrosillo N
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):249-64. PubMed ID: 24392752
[TBL] [Abstract][Full Text] [Related]
3. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
4. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
Seifert H; Blondeau J; Dowzicky MJ
Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.
Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN
Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396
[TBL] [Abstract][Full Text] [Related]
9. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017.
Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O
S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955
[TBL] [Abstract][Full Text] [Related]
10. 3-Amino-4-aminoximidofurazan derivatives: small molecules possessing antimicrobial and antibiofilm activity against Staphylococcus aureus and Pseudomonas aeruginosa.
Das MC; Paul S; Gupta P; Tribedi P; Sarkar S; Manna D; Bhattacharjee S
J Appl Microbiol; 2016 Apr; 120(4):842-59. PubMed ID: 26785169
[TBL] [Abstract][Full Text] [Related]
11. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa PA14 Enhances the Efficacy of Norfloxacin against Staphylococcus aureus Newman Biofilms.
Orazi G; Jean-Pierre F; O'Toole GA
J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32661077
[TBL] [Abstract][Full Text] [Related]
14. Biofilm contamination of high-touched surfaces in intensive care units: epidemiology and potential impacts.
Costa DM; Johani K; Melo DS; Lopes LKO; Lopes Lima LKO; Tipple AFV; Hu H; Vickery K
Lett Appl Microbiol; 2019 Apr; 68(4):269-276. PubMed ID: 30758060
[TBL] [Abstract][Full Text] [Related]
15. Human Salivary Protein Histatin 5 Has Potent Bactericidal Activity against ESKAPE Pathogens.
Du H; Puri S; McCall A; Norris HL; Russo T; Edgerton M
Front Cell Infect Microbiol; 2017; 7():41. PubMed ID: 28261570
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens.
Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF
Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338
[TBL] [Abstract][Full Text] [Related]
17. Antipathogenic Efficacy of Biogenic Silver Nanoparticles and Antibiofilm Activities Against Multi-drug-Resistant ESKAPE Pathogens.
Khan MH; Unnikrishnan S; Ramalingam K
Appl Biochem Biotechnol; 2024 Apr; 196(4):2031-2052. PubMed ID: 37462813
[TBL] [Abstract][Full Text] [Related]
18. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
19. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
[TBL] [Abstract][Full Text] [Related]
20. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
